壹、活動基本資訊

一、時間：2023/05/17(三)

 二、地點：輔大醫院六樓任顯群醫學講堂

 三、辦理單位：輔大醫院人文處、輔大醫院院長室、輔大醫院教學部

 四、講者：國立台灣大學醫學院附設醫院 –高嘉宏 副院長

 五、對象：全院同仁

 六、活動摘要：

題目：Precision Medicine in the Management of Chronic Hepatitis B

The advancement of investigation tools and electronic health records enables a paradigm shift from guideline-specific therapy toward patient-specific precision medicine. The multiparametric and large detailed information necessitates novel analyses to explore the insight of diseases and to aid the diagnosis, monitoring, and outcome prediction. In the context of hepatology, chronic hepatitis B (CHB) infection leads to clinically hetero­geneous disease outcomes across the world, and several existing viral markers have been used to diagnose, monitor treatment responses and predict risk of disease progression to liver cirrhosis/hepatocellular carcinoma (HCC) in CHB patients. On the basis of innovations in molecular medicine and genomics, novel hepatitis B viral and host biomarkers associated with diagnosis and disease progression of chronic hepatitis B virus (HBV) infection have been elucidated. For large-scale screening of CHB, point-of-care tests provide simple and rapid methods for HBV detection. Regarding the monitoring of CHB progression, hepatitis B core-related antigen (HBcrAg) and HBV RNA are positively correlated with intrahepatic cccDNA. The serum HBcrAg level is a predictor of cirrhosis and HCC development, whereas HBV RNA is associated with the response of antiviral therapy and can serve as a biomarker to predict viral relapse after discontinuation of antiviral therapy. Total anti-HBc level may reflect the host immune response to HBV infection and is significantly correlated with the severity of hepatic inflammation and fibrosis as well as HBsAg seroclearance. For HCC surveillance, Mac-2 binding protein glycosylation isomer (M2BPGi) is associated with HCC development in treatment-naïve patients and at virological remission in those on antiviral therapy. In conclusion, these novel biomarkers help clinicians monitor the natural course and treatment response of CHB. Future efforts from academic and industry partners are required to establish artificial intelligence (AI) including machine learning and deep learning tools for the precision management of CHB patients.

題目：臺大醫院研究環境營造與制度建立

臺大醫院是國立臺灣大學醫學院的附設醫院，過去128年來臺大醫院一直致力於照顧台灣民眾的健康，並為政府單位提供公共衛生政策的建言。歷任院長跟醫學校區的教授們也殫精竭慮，希望為臺灣這一塊土地做出更多的貢獻。臺大醫院身為世界百大內研究型大學的附設醫院，有教學、研究跟服務三大任務，其中優質教學的目的是為了培育優秀的醫事人員，乃是我們的天職；創新服務就是為了維護民眾的健康福祉，免於疾病的恐懼，這是我們的責任；而卓越研究更是我們內建的基因跟使命，屬重中之重。藉由前沿基礎跟臨床研究所獲得的實證醫學成果，可以適時地應用到臨床診療以及教學上面，使臨床診療更具成效，並使教學內容更為豐富。過去臺大醫院在多項醫療領域上有非常傑出的研究表現，在國際上頗具聲譽，但我們並不以此自滿，將會繼續傳承過去光榮的研究傳統，致力於培養下一個世代的年輕研究人員，投注更多的資源以建立完善的制度跟環境，並與國內外產官學研單位合作，發展尖端的研究跟服務項目如智慧醫療、精準健康、再生醫學、免疫治療、細胞治療跟核酸治療等。這幾年在院長領導跟醫研部同仁的共同努力下，臺大醫院的研究、教學跟服務已經邁入新的里程碑，躋身世界一流的大學醫院，也符合國人對追求優質健康跟全人照護的期望。

貳、活動照片

參、活動海報